2247398-68-9
Chemical Structure
Py-MAA-Val-Cit-PAB-MMAE
- CAS No.: 2247398-68-9
- Formula:C72H111N13O16S
- Molecular Weight:1446.79
IUPAC Name: 4-((S)-2-((S)-2-(2-((3-(3,5-diacryloyl-1,3,5-triazinan-1-yl)-3-oxopropyl)thio)acetamido)-3-methylbutanamido)-5-ureidopentanamido)benzyl ((S)-1-(((S)-1-(((3R,4S,5S)-1-((S)-2-((1R,2R)-3-(((1S,2R)-1-hydroxy-1-phenylpropan-2-yl)amino)-1-methoxy-2-methyl-3-oxo
InChIKey: ASDXMJBJAKMFHO-NGASZDMPSA-N
SMILES: O[C@@H](C1=CC=CC=C1)[C@@H](C)NC([C@H](C)[C@H]([C@@]2([H])N(CCC2)C(C[C@@H](OC)[C@H]([C@@H](C)CC)N(C)C([C@H](C(C)C)NC([C@H](C(C)C)N(C)C(OCC3=CC=C(C=C3)NC([C@H](CCCNC(N)=O)NC([C@H](C(C)C)NC(CSCCC(N4CN(CN(C4)C(C=C)=O)C(C=C)=O)=O)=O)=O)=O)=O)=O)=O)=O)OC)=O
Biological Activity: Py-MAA-Val-Cit-PAB-MMAE is a drug-Linker conjugates for ADC, which is composed of MMAE (HY-15162) and Py-MAA-Val-Cit-PAB linked. Py-MAA-Val-Cit-PAB-MMAE can be used to synthesize Zapadcine-3a, which targeting TRAILR2. Zapadcine-3a has broad-spectrum anti-tumor activity, and can specifically kill TRAILR2-positive tumors[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Py-MAA-Val-Cit-PAB-MMAE | 98.46% | Py-MAA-Val-Cit-PAB-MMAE is a drug-Linker conjugates for ADC, which is composed of MMAE (HY-15162) and Py-MAA-Val-Cit-PAB linked. Py-MAA-Val-Cit-PAB-MMAE can be used to synthesize Zapadcine-3a, which targeting TRAILR2. Zapadcine-3a has broad-spectrum anti-tumor activity, and can specifically kill TRAILR2-positive tumors. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Zheng Dexia, et al. Anti-tumor necrosis factor-related apoptosis-inducing ligand receptor 2 (TRAILR2) antibody-drug conjugate (ADC) and its pharmaceutical application in antineoplastic therapy: China, CN108452320. 2018-08-28.
- [2]. Fang, et al. Anti-c-Met antibody drug conjugates and their applications. TWI817190B. 2023.10.01
- [3]. Fang, et al. Anti-mesothelin antibody and antibody-drug conjugate thereof. WO2019223579A1. 2019-11-28.
